Klee Justin B.'s Form 4 filing
Amylyx Pharmaceuticals, Inc. (AMLX) · filed Apr 2, 2025
- Accession no.
- 0000950170-25-049495
- Filed
- Apr 2, 2025
- Trade date
- Mar 31, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $74.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Klee Justin B.CIK 0001898314 | Director, Officer (Co-Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | Common Stock | SSaleDisposed | −21,490 | $3.46 | −$74,355.4 | 3,355,276 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.